1. Home
  2. CLDX vs GENB Comparison

CLDX vs GENB Comparison

Compare CLDX & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celldex Therapeutics Inc.

CLDX

Celldex Therapeutics Inc.

HOLD

Current Price

$31.29

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$12.21

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CLDX
GENB
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
CLDX
GENB
Price
$31.29
$12.21
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
$44.50
N/A
AVG Volume (30 Days)
882.3K
733.7K
Earning Date
05-07-2026
05-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$12,743,000.00
N/A
Revenue This Year
$111.39
N/A
Revenue Next Year
$235.85
N/A
P/E Ratio
N/A
N/A
Revenue Growth
87.78
N/A
52 Week Low
$14.40
$11.00
52 Week High
$31.85
$13.95

Technical Indicators

Market Signals
Indicator
CLDX
GENB
Relative Strength Index (RSI) 61.73 47.80
Support Level $24.70 $11.26
Resistance Level N/A $13.70
Average True Range (ATR) 1.39 1.07
MACD -0.06 -0.02
Stochastic Oscillator 81.42 40.74

Price Performance

Historical Comparison
CLDX
GENB

About CLDX Celldex Therapeutics Inc.

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: